Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
NCT02392494
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
MK-1075
Sponsor
Merck Sharp & Dohme LLC